PUNE, India, October 6, 2015 /PRNewswire/ --

Market research titled Urinary Tract Infections - Pipeline Review, H1 2015 provides data and information that helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on Urinary Tract Infections pipeline spread across 137 pages, analyzing 22 companies, 33 drug profiles and supported with 44 tables and 16 figures is now available at http://www.rnrmarketresearch.com/urinary-tract-infections-pipeline-review-h1-2015-market-report.html .

This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies mentioned in this Urinary Tract Infections pipeline H1 2015 review report include Achaogen Inc., Adenium Biotech ApS, AstraZeneca PLC, ConjuGon, Inc., Cubist Pharmaceuticals, Inc., Da Volterra, DexTech Medical AB, FOB Synthesis, Inc., GlycoVaxyn AG, Melinta Therapeutics, Inc, Merck & Co., Inc., MerLion Pharmaceuticals Pte Ltd, Nabriva Therapeutics AG, NovaBay Pharmaceuticals, Inc., Nymox Pharmaceutical Corporation, Osel Inc., Paratek Pharmaceuticals, Inc., Sequoia Sciences, Inc., Shionogi & Co., Ltd., Syntiron LLC, Tetraphase Pharmaceuticals Inc. and The Medicines Company. Drug profiles discussed in this report are (ceftaroline fosamil + avibactam sodium), (ceftazidime + avibactam sodium), (ceftolozane sulfate + tazobactam sodium), (meropenem+ RPX-7009), AA-139, auriclosene, C-1205, CatDex, cefepime, DAV-210, delafloxacin, Drugs to Inhibit COX-2 for Urinary Tract Infections, EBX-002, eravacycline, Escherichia coli vaccine, extraintestinal pathogenic escherichia coli vaccine, finafloxacin, FSI-1686, GP-4, klebsiella pneumoniae vaccine, LACTIN-V, Micselon, Nu-2, Nu-3, NXB-4221, omadacycline, plazomicin sulfate, Proteins for Infectious Diseases, relebactam, S-649266, Small Molecules to Inhibit 23S Ribosomal RNA for Infections, Vaccine for Urinary Tract Infection and ZTI-01.  Order a copy of Urinary Tract Infections - Pipeline Review, H1 2015 market research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=308838 .

The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities.The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects while summarizing all the dormant and discontinued pipeline projects. A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Urinary Tract Infections pipeline on the basis of target, MoA, route of administration and molecule type, latest news and deals relating related to pipeline products.

Another research on infectious disease therapeutics titled Coronavirus Infection - Pipeline Review, H2 2015 is spread across 62 pages, talks about 8 companies involved in coronavirus infection therapeutics development and 13 drug profiles. Comprehensive table of contents, list of tables and figures provided in this research and more on this report is available at http://www.rnrmarketresearch.com/coronavirus-infection-pipeline-review-h2-2015-market-report.html .

Explore more reports on Infectious Diseases Therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us: 

G+ / Google Plus: https://plus.google.com/u/0/104156468549256253075/

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research